NCT06891157View on ClinicalTrials.gov

Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes

PHASE2RecruitingINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

August 20, 2024

Primary Completion Date

August 20, 2027

Study Completion Date

August 20, 2027

Conditions
ChidamideR-CHOP ChemotherapyDLBCL - Diffuse Large B Cell LymphomaDouble-expressor Lymphoma (DEL)
Interventions
DRUG

Chidamide plus R-CHOP

Chidamide Plus R-CHOP (Rituximab、Cyclophosphamide、Doxorubicin、Vincristine and Prednisone)

Trial Locations (1)

210000

RECRUITING

The First Affiliated Hospital with Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER